| __timestamp | Insmed Incorporated | Merck & Co., Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 33534999 | 16768000000 |
| Thursday, January 1, 2015 | 1982000 | 14934000000 |
| Friday, January 1, 2016 | 2438000 | 13891000000 |
| Sunday, January 1, 2017 | 2901000 | 12775000000 |
| Monday, January 1, 2018 | 2423000 | 13509000000 |
| Tuesday, January 1, 2019 | 24212000 | 14112000000 |
| Wednesday, January 1, 2020 | 39872000 | 13618000000 |
| Friday, January 1, 2021 | 44152000 | 13626000000 |
| Saturday, January 1, 2022 | 55126000 | 17411000000 |
| Sunday, January 1, 2023 | 65573000 | 16126000000 |
In the ever-evolving pharmaceutical landscape, understanding cost dynamics is crucial. Merck & Co., Inc., a titan in the industry, has consistently maintained a high cost of revenue, averaging around $14.7 billion annually from 2014 to 2023. In stark contrast, Insmed Incorporated, a smaller player, has seen its cost of revenue grow significantly, from approximately $3.4 million in 2014 to $65.6 million in 2023, marking an impressive increase of over 1800%.
While Merck's cost of revenue has shown a steady trend with minor fluctuations, Insmed's growth trajectory highlights its expanding operations and market presence. This comparison not only underscores the scale difference between the two companies but also reflects the dynamic nature of the pharmaceutical sector, where smaller companies can rapidly scale their operations.
Cost of Revenue Comparison: Merck & Co., Inc. vs BeiGene, Ltd.
Cost Insights: Breaking Down Merck & Co., Inc. and Jazz Pharmaceuticals plc's Expenses
Analyzing Cost of Revenue: Merck & Co., Inc. and Amneal Pharmaceuticals, Inc.
Cost Insights: Breaking Down Merck & Co., Inc. and PTC Therapeutics, Inc.'s Expenses
Comparing Cost of Revenue Efficiency: Merck & Co., Inc. vs HUTCHMED (China) Limited
Analyzing Cost of Revenue: Merck & Co., Inc. and Mesoblast Limited
Cost of Revenue: Key Insights for Merck & Co., Inc. and Dyne Therapeutics, Inc.
Cost of Revenue Trends: Biogen Inc. vs Insmed Incorporated
Insmed Incorporated vs Exelixis, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue: Key Insights for Insmed Incorporated and Telix Pharmaceuticals Limited
Cost of Revenue: Key Insights for Insmed Incorporated and Ionis Pharmaceuticals, Inc.
Comparing Cost of Revenue Efficiency: Insmed Incorporated vs Bausch Health Companies Inc.